Featured Articles
-
Meet Barbara Holland, Business Development Director
5/12/2022
Barbara Holland, Business Development Director at Pii, is a bit of a renaissance woman. Learn about her personal interests and why she came out of retirement to work with customers.
-
Manage Risks In Development And Manufacture Of Potent Pharma Products
6/17/2019
Given the variety of potent drugs in development, outsourcing the development and manufacturing to a CDMO experienced in handling a range of products, in a multi-use facility, is an effective strategy.
-
Navigating An Ever-Changing Landscape: The Role Of A CFO In A Private Equity Controlled Pharma Company
The role of Chief Financial Officer for a small-to-mid size pharma company controlled by private equity is a challenging one, especially since pharma companies with limited internal resources often rely on CDMOs for support. Learn how these CFOs can use their CDMOs to be more successful.
-
Applying The Four Dimensions Of Sustainability To Create Capacity That Delivers Results Faster
There are no shortcuts to growing capacity that delivers results faster and maintaining it is difficult. The key ingredient in growing enterprise value is sustainability. Learn how by applying the principle of sustainability using its four dimensions, finite resources are more wisely used with extraordinary results, lead time from concept to commercialization is greatly improved, and patients receive better medications faster.
-
Applying Quality By Design To Pharmaceutical Research And Development
12/1/2020
QbD is often discussed in the context of process development and manufacturing. We focus on QbD applied to R&D to drive better results throughout the drug development process.
-
Innovating During The COVID-19 Pandemic
Pharmaceutics International, Inc., (Pii) is a premier CDMO, offering unparalleled scientific insight and depth of product knowledge, while supplying high-quality dosage forms that enhance the lives of patients worldwide. Pii provides customized and flexible solutions across several dosage forms and has experience with a broad range of compounds.
-
Meet The Scientist — Sam Chia
Sam is responsible for the sterile injectables facility, including four manufacturing suites and housing R&D, quality control, microbiology, and engineering support. He believes his role is most importantly about people – his colleagues and the patients who rely on the drug therapies they develop and manufacture.
-
The Case For Repatriating The Pharmaceutical Supply Chain
The pandemic has broadcast a loud call to bring our pharmaceutical supply chain back to the U.S. to provide greater regulatory control and patient, economic, and workforce benefits.
-
Demystifying Highly Potent API And Cytotoxic Drug Products
The concept of development, process design, and manufacturing of drugs with a HPAPI or cytotoxic compounds should not be a mystery to drug sponsors using a CDMO. Gathering, organizing, and understanding critical risk data related to HPAPIs and cytotoxic drugs ensures appropriate controls are defined from concept to clinical batch manufacturing to commercial-scale manufacturing.
-
How A CDMO Achieves Finished Product Lyophilization With Limited And Expensive API
6/27/2022
Agile, cost-effective lyophilization services can accelerate the development of complex drug candidates that present stability challenges, but lyophilization can be challenging, expensive, and time-consuming.